Skip to main content

View full-text article in PMC

. 2012 Jan 18;3(3):151–160. doi: 10.1021/cn200117j

Table 8. Anthracene and Phenanthrene Derivatives as LRRK2 Inhibitors.

		IC₅₀
no.	name	wild-type LRRK2	LRRK2-G2019S	substrate	substrate selectivity^a	in vivo	lit.
15	SP600125	3100 nM^b	5000 nM^b	MBP^c	2		(58)
16	Damnacanthal	7810 nM^b	9450 nM^b	MBP^c	2		(58)
17	LDN-73794	3500 nM^d		PLK-peptide	2		(68)
18	LDN-22684^e	6900 nM^f	6100 nM^f	PLK-peptide			(69)

^a

Number of all kinases, including LRRK2.

^b

GST-LRRK2 (wt/G2019S).

^c

Myelin basic protein (MBP).

^d

Purified from BAC-transgenic mouse brain.

^e

Non-ATP competitive.

^f

Human LRRK2 (970-2527; wt/G2019S).